1-8 of 8
Edward B. Garon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characteristics of a CCL21 Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer

Michael S. Oh, Camelia Dumitras, Ramin Salehi-Rad, Linh M. Tran, Kostyantyn Krysan, Raymond J. Lim, Zhe Jing, Shahed Tappuni, Aaron Lisberg, Edward B. Garon, Steven M. Dubinett, Bin Liu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF13.
https://doi.org/10.1158/1535-7163.MCT-24-0435
Published: 11 December 2024
View article titled, Characteristics of a <em>CCL21</em> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer
Open the PDF for Characteristics of a <em>CCL21</em> Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract LBA039: Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial

Edward B. Garon, Andrea Ardizzoni, Fabrice Barlesi, Byoung Chul Cho, Pedro De Marchi, Yasushi Goto, Dariusz Kowalski, Shun Lu, David R. Spigel, Michael Thomas, James Chih-Hsin Yang, Sabine Turri, Wen Zhou, Teri Kreisl, Luis Paz-Ares
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): LBA039.
https://doi.org/10.1158/1535-7163.TARG-21-LBA039
Published: 01 December 2021
View article titled, Abstract LBA039: Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial
Journal Articles

Abstract A029: Biomarker analysis of patients with METΔex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study

Rebecca S. Heist, Edward B. Garon, Daniel S.W. Tan, Harry J.M. Groen, Takashi Seto, Egbert F. Smit, Lauren Fairchild, Alejandro Balbin, Ming Yan, Monica Giovannini, Mikhail Akimov, Banu Sankaran, Ngozi Nwana, Juergen Wolf
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A029.
https://doi.org/10.1158/1535-7163.TARG-19-A029
Published: 01 December 2019
View article titled, Abstract A029: Biomarker analysis of patients with <em>MET</em>Δex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study
Journal Articles

Abstract B98: Serial evaluation of PD-L1 expression on circulating tumor cells (CTCs)

Jonathan W. Goldman, Manjima Dhar, James Che, Edward B. Garon, Siwen Hu-Lieskovan, Melissa Matsumoto, Brian R. Wolf, James M. Carroll, Matthew J. Crabtree, D. Andrew Tucker, Jennifer Strunck, Elodie Sollier, Rajan Kulkarni, Dino Di Carlo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B98.
https://doi.org/10.1158/1535-7163.TARG-15-B98
Published: 01 December 2015
View article titled, Abstract B98: Serial evaluation of PD-L1 expression on circulating tumor cells (CTCs)
Journal Articles

Abstract PL02-02: Progress in lung cancer treatment with immunotherapy

Edward B. Garon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): PL02-02.
https://doi.org/10.1158/1535-7163.TARG-15-PL02-02
Published: 01 December 2015
View article titled, Abstract PL02-02: Progress in lung cancer treatment with immunotherapy
Journal Articles

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avsar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 890–900.
https://doi.org/10.1158/1535-7163.MCT-12-0998
Published: 09 June 2013
View article titled, The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Open the PDF for The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth in another window
Includes: Supplementary data
Journal Articles

Identification of Common Predictive Markers of In vitro Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines

Edward B. Garon, Richard S. Finn, Wylie Hosmer, Judy Dering, Charles Ginther, Shahriar Adhami, Naeimeh Kamranpour, Sharon Pitts, Amrita Desai, David Elashoff, Tim French, Paul Smith, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 1985–1994.
https://doi.org/10.1158/1535-7163.MCT-10-0037
Published: 07 July 2010
View article titled, Identification of Common Predictive Markers of <em>In vitro</em> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines
Open the PDF for Identification of Common Predictive Markers of <em>In vitro</em> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non–Small Cell Lung Cancer Cell Lines in another window
Includes: Supplementary data
Journal Articles

Abstract B19: Interim safety results of a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (Ca4p) with carboplatin, paclitaxel and bevacizumab in stage IIIB/IV non‐squamous non‐small cell lung cancer

Edward B. Garon, Fairooz Kabbinavar, Jai Balkissoon, Shaio‐Ping Lu, James A. Neidhart, Nash Gabrail, Moacyr R. de Oliveira
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B19.
https://doi.org/10.1158/1535-7163.TARG-09-B19
Published: 10 December 2009
View article titled, Abstract B19: Interim safety results of a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (Ca4p) with carboplatin, paclitaxel and bevacizumab in stage IIIB/IV non‐squamous non‐small cell lung cancer